For hematopoietic stem cell transplantation (HCT) HLA 10/10 (HLA-A, B, C, DRB1, DQB1) matched donors are optimal, but are not available for all patients. The identification of permissive/non-immunogenic mismatches may improve the outcome of HLA mismatched transplants. We hypothesize that HLA alleles identical within the antigen recognition domain (ARD), but mismatched outside the peptide binding groove or α-helices are often permissive mismatches. We evaluated the functional impact of non-ARD mismatches by performing in vitro functional T cell assays. Cytotoxic T Lymphocyte precursor assays were performed for 23 HLA class I mismatches and 96% (22 out of 23) were negative. Mixed lymphocyte reaction assays were conducted on 10 HLA class II mismatches and all were negative. However, 4 out of 10 combinations were positive in the Elispot and all involved one direction: a DRB1*14:01/DRB3*02:01 responder against a DRB1*14:54/ DRB3*02:02 stimulator. These positive responses were confirmed by Primed Lymphocyte Testing and the DRB1* mismatch seemed to be responsible for the response. In conclusion, HLA mismatches with amino-acid differences outside the ARD are not very immunogenic. However, in some cases weak T cell reactivity in vitro can be observed. The impact of these responses on clinical outcome of HCT remains to be established.
Introduction
When a hematopoietic cell transplantation (HCT) is the choice of treatment, a fully HLA-A, B, C, DRB1, and DQB1 matched donor is optimal. In case it is not possible to find a full HLA matched donor, a single HLA mismatch can be accepted although, it is associated with lower overall and disease free survival, as well as with higher treatment related mortality and more acute GVHD [1, 2] .
Mismatches between HLA molecules can either be located inside or outside the antigen recognition domain (ARD). For HLA class I the ARD is formed by amino acids encoded by exons 2 and 3 [3] . For HLA Class II, including HLA-DRB1, the ARD is encoded only by exon 2. For HLA-DR, the β genes can be considered to be functionally relevant in HCT as the β1 domain of an HLA molecule is directly involved in the alloimmune recognition [4] . However, the functional relevance in HCT for mismatches located outside the ARD is not yet known.
In this study we first examined the immunogenicity of the various HLA class I mismatches by the Cytotoxic T Lymphocyte precursor (CTLp) test which was performed for various combinations. The difference between DRB1*14:01 and DRB1*14:54 is an example of an HLA mismatch outside the ARD. While the β1 domain is identical for these two DRB1 antigens, they differ in their β2 domain at position 112, exon 3 [5] . Because this substitution occurs outside the ARD, there is no difference in peptide binding inside the groove of the HLA molecule. On the basis of molecular modeling however, the possibility for a change in binding to the costimulatory molecule CD4 is estimated as unlikely but is not ruled out [4, 6] . The mismatch of DRB1*14:01 vs DRB1*14:54 is often accompanied by a second mismatch in DRB3 through strong linkage disequilibrium (LD). DRB1*14:01 is often associated with DRB3*02:01 while DRB1*14:54 is often associated with DRB3*02:02 [7] . These two DRB3 alleles differ in two separate substitutions, one inside and one outside the ARD. Because DRB3 has a lower expression level than DRB1, the DRB3 mismatch may not influence the outcome of HCT [8] . The in vitro cellular response between DRB1*14:01/DRB3*02:01 vs. DRB1*14:54/ DRB3*02:02 mismatched donors was investigated by the IFN-γ ELIspot, Mixed Lymphocyte Culture (MLC) and the Primed Lymphocyte Test (PLT).
Material and methods

Donor selection and sample collection
CTLp assays were performed in 23 donor-recipient pairs registered by the Europdonor Foundation. Patients diagnosed with either malignant or non-malignant diseases were adults and children referred for HCT in one of three Dutch transplant centers: Leiden (LUMC), Rotterdam (Erasmus) and Utrecht (UMCU). The unrelated donors were derived from Europdonor Foundation or from international donor registries. Most donor-recipient pairs were matched at 9 out of 10 alleles at allele-level resolution with a single allele or antigen non-ARD mismatch at the HLA-A, B or C locus (17 of the 23 pairs). (see Table 1 : pairs 1-23). Some of the pairs had additional mismatches at C (pair 14), DRB1 (pairs 9,10) or DQB1 (pairs 15, 18, 20) . All CTLp assays were performed as part of routine clinical work-up in preparation for donor selection for allogeneic transplantation. The data for this study were collected retrospectively and anonymously from laboratory records.
Regarding the class II mismatched pairs, queries were conducted by the Be The Match Registry® to identify volunteer donors with genotypes that only differed for DRB1*14:01 and *14:54. Stored samples from the Be The Match Registry repository were high resolution (2nd field) HLA typed for HLA-A, B, C, DRB1/3/4/5, DQB1 and DPB1. Additional testing of exon 3 was performed to resolve the DRB1*14:01/54 alleles. This typing resulted in 9 genotype pools of fully matched registry members containing both the DRB1*14 alleles and DRB3*02:01/02. (Table 2 : pairs 24-36). All participating donors provided informed consent to participate in research under a National Marrow Donor Program Institutional Review Board 
CTLp frequency analysis
The CTLp test was performed as described by Zhang et al. [9] . Briefly, graded numbers (from 50,000 cells/well down to 781 in twofold dilutions) of PBMCs from the responder were cultured in 24 replicates with 50,000 irradiated (30 Gy) stimulator cells. After 7 days of culture in RPMI (10% heat-inactivated pooled human serum, 15 U/ml of rIL-2 (Ortho, USA)), each well was individually tested for cytolytic activity against 51 Cr-labeled target cells (PHA blasts of the stimulator). As a negative control, responder cells were also tested with autologous target cells. The release of 51 Cr in the supernatant was assayed in a gamma-counter. Microcultures were considered cytolytic if the observed chromium release exceeded the spontaneous release plus 3 standard dilutions. The CTLp frequencies expressed as the number of precursor cells in 10 6 PBMC, 95% confidence interval, and p value were calculated by the jack-knife version of the maximum likelihood method as described by Strijbosch et al. [10] .
IFN-γ ELIspot
PBMC's were thawed and diluted in culture medium (RPMI with 10% human serum). Triplicates of 1 × 10 5 responder cells and 2 × 10 5 (45 Gray irradiated) stimulator cells, were set up in 96 well round bottom plates (Costar) on day 0 and cultured at 37°C and 5% CO 2 . On day 5 the cells were transferred to ELIspot plates (nitrocellulose, Merck Millipore), which were previously coated with anti-IFN-γ antibodies (Mabtech). After an overnight incubation the cells were washed away and spots were developed using biotinylated anti-IFN-γ antibodies (Mabtech), ALPstreptavidin (Sigma) and BCIP NBT substrate (Mabtech). All antibody concentrations and incubations were used as recommended by the manufacturers. Plates were analyzed on AID/Biosys readers. The number of spots was used to calculate the relative response: as a percentage of the response against a full HLA mismatched control, corrected for background. A relative response of 10-20% is called weak, below 10% is negative and above 20% is a strong response [11] . H was added to each well. On day 6 the cells were harvested (Skatron) and the thymidine incorporation was measured (Wallac). The counts per minute (CPM) were used to calculate the relative response: as a percentage of the response against a full HLA mismatched control, corrected for background. A relative response of 10-20% is called weak, below 10% negative and above 20% strong [11] .
Primed Lymphocyte test (PLT)
Cultures were set up on day 0 in 24 well plates containing 1 × 10 6 responder cells and 1 × 10 6 (30 Gray irradiated) stimulator cells per well and cultured for 7 days. After the first culture the cells were collected and counted with eosine to determine the amount of viable cells. The viable cells were restimulated with fresh stimulator cells (30 Gray irradiated) of the same donor as used in the previous culture [12] . The cells were cultured in the ratio 1 (viable): 10 (stimulator) with the addition of 60 IU of IL-2 per ml culture medium. After another 7 days of culturing the cells were harvested and counted.
Triplets of 1 × 10 4 responder cells and 1 × 10 5 (30 Gray irradiated) stimulator cells, were set up in 96 well round bottom plates and cultured. After 48 h, 1 µCi 3 H was added to each well. After another 24 h of incubating the cells were harvested and the thymidine incorporation was measured.
Results
CTLp frequencies performed on HLA Class I non-ARD mismatches Table 1 .
Alloimmune responses measured in IFN-γ ELIspot and MLC for HLA Class II
Five responder-stimulator pairs were simultaneously tested in both directions in the IFN-γ ELIspot and MLC. These five pairs were fully HLA matched (including HLA-DPB1) except for the mismatch DRB1*14:01/DRB3*02:01 vs. DRB1*14:54/DRB3*02:02 (Fig. 1a) . In two out of five pairs, a weak positive response was found when DRB1*14:01/DRB3*02:01 responder cells were stimulated with DRB1*14:54/DRB3*02:02 stimulators in the IFN-γ ELIspot (pair 26 and 28). In the MLCs no responses above the 10% threshold were observed. However, when tested in the other direction (DRB1*14:54/DRB3*02:02 responder vs. DRB1*14:01/DRB3*02:01 stimulator), none of the pairs showed a positive response in either the IFN-γ ELIspot or MLC.
Next we tested whether a responder that does not respond, will also not respond against a different stimulator with the same HLA mismatch. Pair 25 showed no response in the IFN-γ ELIspot and MLC (Fig. 1b) . For this responder, two different stimulators with the same full HLA typing as the previous DRB1*14:54/DRB3*02:02 positive stimulator, were tested again in both directions both in the ELIspot and MLC (pairs 29 and 30). In the IFN-γ ELIspot, a weak positive response against one out of three stimulators was found (Fig. 1b) . Similarly to the data obtained in the original tests (Fig. 1a) , the response was higher in the direction of DRB1*14:01/DRB3*02:01 vs. DRB1*14:54/ DRB3*02:01 even when a response did not exceed the 10% cut off.
The reactivity found for a weak but positive responder is illustrated for donor pair 26 in Fig. 2 . The positive response of a fully mismatched combination is set at 100% and the response against the stimulator which is DRB1/DRB3 mismatched calculated relative to this response.
Alloimmune response measured in IFN-γ ELIspot and PLT
To check whether the IFN-γ ELIspot was sensitive enough to detect a weak alloimmune response we compared those results in a PLT. In the PLT, responder cells were primed against an HLA mismatch for two weeks and then restimulated for 48 h. Responder cells will only respond against the HLA antigens with which the priming took place. Priming of the responder cells may reveal a weak response not picked up in the IFN-γ ELIspot.
Due to the limited number of cells available, it was only possible to perform the test in one direction, DRB1*14:01/ DRB3*02:01 vs. DRB1*14:54/DRB3*02:01.
Within the three pairs tested (pairs 31-33) the first pair, 31, showed no response in the DRB1*14:01/DRB3*02:01 vs. DRB1*14:54/DRB3*02:02 direction. The second pair, pair 32, showed no response in the IFN-γ ELIspot but did show a response in the PLT. The third pair, 33, showed a response in both the IFN-γ ELIspot and PLT assays (Fig. 3) .
Of the 10 combinations tested in the IFN-γ ELIspot assay in the DRB1*14:01/DRB3*02:01 vs. DRB1*14:54/ DRB3*02:02 direction, four pairs showed a positive response (pairs 26,28,30,33). The observation that 40% of the mismatched pairs do respond is a lower estimate than was previously seen. One of the two previously negative pairs, showed a positive response in the PLT. For this reason we carefully conclude that a positive reaction can be expected in at least 40% of the pairs.
Is the observed alloimmune response directed against the DRB1 or DRB3 mismatch?
The PLT test was used to determine which of the HLA antigens, DRB1 or DRB3, is responsible for the response found above. Despite the strong LD, DRB1*14:01 is often associated with DRB3*02:01 while DRB1*14:54 is often associated with DRB3*02:02, we could select a single DRB1 and DRB3 mismatched pairs for each case. For pair 26, of which the DRB1*14:01/DRB3*02:01 positive responder showed a weak positive reaction in the IFN-γ ELIspot (Fig. 1) , a new stimulator with only the DRB1*14:54 as a repeated HLA mismatch was found (new pair = pair 34). There were other mismatches, but no priming against these had taken place in the primary culture. In the PLT the DRB1*14:01/DRB3*02:01 responder was primed against the DRB1*14:54/ DRB3*02:02 positive stimulator and then tested in the 48 h MLC. The DRB1*14:01/DRB3*02:01 responder showed a weak positive reaction against the DRB1*14:54/ DRB3*02:02 stimulator, a strong positive reaction against the DRB1*14:54 single repeat mismatched stimulator, and a negative reaction towards a non-repeat HLA mismatched control (Fig. 4a) .
To test the response after priming with the DRB3*02:01 vs. DRB3*02:02 mismatch, we used a pair that was mismatched for the DRB3 but not for the DRB1 (pair 35 and 36). The PLT showed no response in either direction. This was an expected result based on the initial findings of the IFN-γ ELIspot showing that DRB1*14:54/DRB3*02:02 responders did not show a positive response against DRB1*14:01/DRB3*02:01 stimulators (Fig. 4b ).
Discussion
Our previous study evaluating the cytotoxic T-lymphocyte precursor (CTLp) frequencies directed against incompatibilities at the HLA-A, -B, and -C loci in donor-recipient pairs showed a significant correlation between HLA class I incompatibilities and high CTLp frequencies. However, in case of a HLA-C*03:03/-C*03:04 mismatch no CTL precursors were found [13] .
A combined study of North-American centers and the CIBMTR was performed with a total of 7349 HCT from unrelated donors included 4779 pairs matched for 8/8 alleles and 1854 matched for 7/8 alleles. They analyzed the association between the type of HLA mismatch and clinical outcomes with an adjustment for other clinical risk factors. This revealed that the 7/8 C*03:03/C*03:04 mismatch group was not significantly different from the 8/8 HLA matched transplants in any transplant related outcome [14] .
The present study shows that 96% (22 out of 23) of CTLp assays that were performed for 23 HLA class I mismatches were negative, and therefore it is very likely that other combinations with a mismatch outside the ARD (exon 5 = transmembrane, exons 6,7 and 8 are intracytoplasmic regions) can be considered as permissive mismatches in the unrelated HCT setting as these combinations will probably have negative CTLp responses.
Bettens and colleagues have shown by using other functional assays that the B*44:27 vs B*44:02 mismatch was not recognized by CTLs in either direction, showing that the frequency of CD8 + CD137 + T cells was comparable to that measured in the autologous stimulation [15] . The fact that one CTLp test was positive (HLA-C*07:06 vs *07:01) might need further confirmation by studying this non-ARD in another donor-recipient pair or by another functional assay, e.g. frequency of CD8 + CD137 + T cells. It is striking that this is the only pair that was mismatched at the amino acid level at 2 positions whereas the others had only amino acid mismatch.
Here we also studied in depth an example of an HLA DRB1 mismatch outside the ARD: the HLA-DRB1*14:01/ *14:54 mismatch. While the β1 domain is identical for these two DRB1 antigens, they differ in their β2 domain at one amino acid, positioned in exon 3 at codon 112. On the basis of the crystal structure of an HLA-DR-T cell receptor complex, the polymorphism is not located at the site for Ag binding or in a position to affect the interaction with the T-cell receptor. For this reason similar peptide presentation properties are expected. However, we do observe some (weak) responses in at least 40% of the tested combinations making use of a highly sensitive PLT approach. Indirect presentation in which HLA-DR derived peptides are presented in HLA-DR could possibly explain this observation [16] .
Whether the response observed in vitro is caused by a change in binding to the co-stimulatory molecule CD4 is not known as there is a small chance that the binding to CD4 is influenced by this difference [4, 6] .
Another explanation might be that the observed response was caused by the difference in the DRB3 gene. However, the results from the PLT as depicted in Fig. 4 suggest that DRB1 is inducing the cellular response and not DRB3. The fact that DRB3 is not causing a cellular (in vitro) response is not a surprise as it has been reported that the DR52 protein expression (coded for by the DRB3 genes) is considerably lower when compared to HLA-DR expression (DRB1 genes) (8) , although others have observed that DRB3 could activate T cells [17, 18] .
Pasi et al. [19] addressed the clinical outcome of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/02:02 mismatches in unrelated HCT. Their findings suggest that it is unlikely that disparities at exon 3 of the HLA-DRB1 gene influence the outcome after HCT. However the patients studied were DRB1*14:01 and the donors therefore DRB1*14:54 which is the direction of host vs graft. As we found only positive responses in the DRB1*14:01 individuals stimulated by DRB1*14:54 we expect that this HLA difference may have a possible impact on the graft vs. host response when donors are HLA-DRB1*14:01 which was not the case in this study. Xiao et al. [4] showed that >88,000 transplants would be required to determine the clinical relevance of a HLA-DRB1*14:01 vs. DRB1*14:54 mismatch. With the data presented here showing that the direction of the mismatch plays a role this number should ever be larger as a percentage of these mismatches will be in the direction that does not cause a response. In conclusion, mismatches involving positions outside the ARD are not very immunogenic. However, as shown here the directional DRB1*14:01 vs 14:54 mismatch can lead to T cell reactivity in vitro. Strikingly the DRB1*14:54 to 14:01 reactivity is in one direction only. The clinical consequences of this low degree of immunogenicity remain unknown.
Using large cohorts of unrelated transplant patients addressing the clinical outcome of these combinations with a mismatch outside the ARD could definitely prove the permissive state of these allele mismatches.
